238 related articles for article (PubMed ID: 19959674)
1. Measures for assessing subjective effects of potential reduced-exposure products.
Hanson K; O'Connor R; Hatsukami D
Cancer Epidemiol Biomarkers Prev; 2009 Dec; 18(12):3209-24. PubMed ID: 19959674
[TBL] [Abstract][Full Text] [Related]
2. Clinical trials methods for evaluation of potential reduced exposure products.
Hatsukami DK; Hanson K; Briggs A; Parascandola M; Genkinger JM; O'Connor R; Shields PG
Cancer Epidemiol Biomarkers Prev; 2009 Dec; 18(12):3143-95. PubMed ID: 19959672
[TBL] [Abstract][Full Text] [Related]
3. Interventions to reduce harm from continued tobacco use.
Lindson-Hawley N; Hartmann-Boyce J; Fanshawe TR; Begh R; Farley A; Lancaster T
Cochrane Database Syst Rev; 2016 Oct; 10(10):CD005231. PubMed ID: 27734465
[TBL] [Abstract][Full Text] [Related]
4. Potential reduced exposure products (PREPs) for smokeless tobacco users: clinical evaluation methodology.
Gray JN; Breland AB; Weaver M; Eissenberg T
Nicotine Tob Res; 2008 Sep; 10(9):1441-8. PubMed ID: 19023835
[TBL] [Abstract][Full Text] [Related]
5. Evaluating oral noncombustible potential-reduced exposure products for smokers.
Blank MD; Eissenberg T
Nicotine Tob Res; 2010 Apr; 12(4):336-43. PubMed ID: 20159791
[TBL] [Abstract][Full Text] [Related]
6. Methods used in internal industry clinical trials to assess tobacco risk reduction.
Rees VW; Kreslake JM; O'Connor RJ; Cummings KM; Parascandola M; Hatsukami D; Shields PG; Connolly GN
Cancer Epidemiol Biomarkers Prev; 2009 Dec; 18(12):3196-208. PubMed ID: 19959673
[TBL] [Abstract][Full Text] [Related]
7. Smoker and ex-smoker reactions to cigarettes claiming reduced risk.
Shiffman S; Pillitteri JL; Burton SL; Di Marino ME
Tob Control; 2004 Mar; 13(1):78-84. PubMed ID: 14985602
[TBL] [Abstract][Full Text] [Related]
8. Evaluating the acute effects of oral, non-combustible potential reduced exposure products marketed to smokers.
Cobb CO; Weaver MF; Eissenberg T
Tob Control; 2010 Oct; 19(5):367-73. PubMed ID: 19346218
[TBL] [Abstract][Full Text] [Related]
9. Surveillance of tobacco industry retail marketing activities of reduced harm products.
Slater S; Giovino G; Chaloupka F
Nicotine Tob Res; 2008 Jan; 10(1):187-93. PubMed ID: 18188759
[TBL] [Abstract][Full Text] [Related]
10. Potential reduced exposure products (PREPs) in industry trial testimony.
Wayne GF
Tob Control; 2006 Dec; 15 Suppl 4(Suppl 4):iv90-7. PubMed ID: 17130630
[TBL] [Abstract][Full Text] [Related]
11. Use of Potentially Reduced Exposure Tobacco Products Among American Indian Smokeless Tobacco Users: Associations With Cessation Behaviors and Cotinine Levels.
Comiford AL; Rhoades DA; Dvorak JD; Ding K; Mehta T; Spicer P; Wagener T; Doescher MP
Public Health Rep; 2020 Jan; 135(1):141-149. PubMed ID: 31835016
[TBL] [Abstract][Full Text] [Related]
12. Recommendations regarding interventions to reduce tobacco use and exposure to environmental tobacco smoke.
Task Force on Community Preventive Services
Am J Prev Med; 2001 Feb; 20(2 Suppl):10-5. PubMed ID: 11173214
[No Abstract] [Full Text] [Related]
13. New tobacco products: do smokers like them?
Caraballo RS; Pederson LL; Gupta N
Tob Control; 2006 Feb; 15(1):39-44. PubMed ID: 16436404
[TBL] [Abstract][Full Text] [Related]
14. What do adult smokers think about ads and promotional materials for PREPs?
O'Hegarty M; Richter P; Pederson LL
Am J Health Behav; 2007; 31(5):526-34. PubMed ID: 17555383
[TBL] [Abstract][Full Text] [Related]
15. Evaluation of behavioural, chemical, toxicological and clinical studies of a tobacco heated product glo™ and the potential for bridging from a foundational dataset to new product iterations.
Goodall S; Gale N; Thorne D; Hadley S; Prasad K; Gilmour I; Miazzi F; Proctor C
Toxicol Rep; 2022; 9():1426-1442. PubMed ID: 36561950
[TBL] [Abstract][Full Text] [Related]
16. Abuse liability assessment of tobacco products including potential reduced exposure products.
Carter LP; Stitzer ML; Henningfield JE; O'Connor RJ; Cummings KM; Hatsukami DK
Cancer Epidemiol Biomarkers Prev; 2009 Dec; 18(12):3241-62. PubMed ID: 19959676
[TBL] [Abstract][Full Text] [Related]
17. Biomonitoring of inhaled complex mixtures--ambient air, diesel exhaust and cigarette smoke.
Scherer G
Exp Toxicol Pathol; 2005 Jul; 57 Suppl 1():75-110. PubMed ID: 16092718
[TBL] [Abstract][Full Text] [Related]
18. [Harm reduction strategy in tobacco control].
Gorini G
Epidemiol Prev; 2011; 35(3-4 Suppl 1):19-32. PubMed ID: 21926451
[TBL] [Abstract][Full Text] [Related]
19. Governments must agree unified approach to use of e-cigarettes, report says.
Mayor S
BMJ; 2013 May; 346():f3537. PubMed ID: 23723461
[No Abstract] [Full Text] [Related]
20. Family and carer smoking control programmes for reducing children's exposure to environmental tobacco smoke.
Baxi R; Sharma M; Roseby R; Polnay A; Priest N; Waters E; Spencer N; Webster P
Cochrane Database Syst Rev; 2014 Mar; (3):CD001746. PubMed ID: 24671922
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
